Safety and Immunogenicity of the Tetravalent Recombinant COVID-19 Protein Vaccine SCTV01E in Children and Adolescents Aged 3 to 17 Years: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial

Safety and Immunogenicity of the Tetravalent Recombinant COVID-19 Protein Vaccine SCTV01E in Children and Adolescents Aged 3 to 17 Years: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial

<b>Background</b>: SCTV01E is a tetravalent recombinant COVID-19 vaccine authorized for emergency use in China for adults 18 years and older but not for those under 18. <b>Objective</b>: This Phase 2 trial assessed the safety and immunogenicity of SCTV01E in healthy children...

Full description

Saved in:
Bibliographic Details
Main Authors: Fengcai Zhu, Ting Huang, Pengfei Jin, Linglin Zhang, Zhongqiang Jin, Wenli Zhang, Dongya Yuan, Zhong Wang, Yusong Deng, Jiaxin Li, Xiao Shen, Yongpan Fu, Jian Li, Xinjie Yang, Jing Li, Liangzhi Xie
Format: Article
Language:English
Published: MDPI AG 2025-01-01
Series:Vaccines
Subjects:
children and adolescents
immunogenicity
safety
multivalent vaccine
SARS-CoV-2
Online Access:https://www.mdpi.com/2076-393X/13/1/43
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/2076-393X/13/1/43

Similar Items